*Developments: Boston Scientific (2004-2015)

Parents

2004: $6.3 billion 2004
2009: The company recorded revenues of $8,050 million during the financial year (FY) ended December 2008, a decrease of 3.7% over FY2007
2009: The net loss of the company was $2,036 million in FY2008, as compared to the net loss of $ 495 million in FY2007.
2009: The operating loss of the company was $1,505 million during FY2008, as compared to the operating loss of $14 million in FY2007.
2010, Boston Scientific reported $1.5 billion in DES sales and held a 33 percent market share in the U.S., lead by its Taxus and Promus stents.
2010: Stryker announces $1.5 billion buyout of Boston Scientific Corp.'s (NYSE:BSX) neurovascular business(2010)
2011: Boston Sci Blazer RF Ablation Catheter Gets EU CE Mark
2011: Boston Scientific gets FDA OK for three defibrillators (2011)
2012: Boston Scientific taps Vodafone, AT&T for mobile patient monitoring
2012: Pain device maker Neuros Medical’s $3.5M round led by Boston Scientific, Glengary (2012)
2014: 7 Products Boston Scientific is Betting on in 2014
2014: Boston Scientific determined to gain ground in medical device sales in emerging markets
2014: Here’s Why Boston Sci’s Partnership with UnitedHealth’s Optum Labs is Important
2014: Legal Woes Beset Boston Scientific
2015: Boston Scientific To Rise Like A Phoenix In 2015